alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 13,301–13,325 of 27,380 studies, newest first · page 533 of 1096.

January 2019 25

  1. 2019 year only

    Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus

    ✓ Peer-reviewed Drug development Advances in experimental medicine and biology

    Key finding: While we identified apomorphine (APO) as a novel drug that promoted intracellular Aβ degradation and improved memory function in an AD mouse model, more recently, we have revealed that APO treatment improves neuronal insulin resistance and activates insulin-degrading enzyme (IDE), a major Aβ-degrading enzyme.

    Full summary, score breakdown and related studies → Original source

  2. 2019 year only

    Protective Effects of Incretin Against Age-Related Diseases

    ✓ Peer-reviewed Drug development Current drug delivery

    Key finding: Drug therapy using incretin has become a new strategy for diabetic treatments due to its significant effects on improving insulin receptors and promoting insulinotropic secretion.

    Full summary, score breakdown and related studies → Original source

  3. 2019 year only

    Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force

    ✓ Peer-reviewed Drug development The journal of prevention of Alzheimer's disease

    Key finding: Both neuropathological and imaging studies indicate that tau first appears in the entorhinal cortex and then spreads to the neocortex.

    Full summary, score breakdown and related studies → Original source

  4. 2019 year only

    Exercise and retinal health

    ✓ Peer-reviewed Brain scans and imaging Restorative neurology and neuroscience

    Key finding: Many ocular diseases (such as glaucoma, diabetic retinopathy, age-related macular degeneration, and traumatic eye injuries) can result in the degeneration of retinal cells and the subsequent loss of vision.

    Full summary, score breakdown and related studies → Original source

  5. 2019 year only

    Early-Stage Identification and Pathological Development of Alzheimer's Disease Using Multimodal MRI

    ✓ Peer-reviewed Brain scans and imaging Journal of Alzheimer's disease : JAD

    Key finding: The current study may shed new light on the pathological mechanism of AD and suggests that whole-brain connectivity may provide potential effective biomarkers for the early-stage diagnosis of AD.

    Full summary, score breakdown and related studies → Original source

  6. 2019 year only

    Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults

    ✓ Peer-reviewed Brain scans and imaging Current Alzheimer research

    Key finding: We found that education level was positively associated with a wide range of complex cognitive domains including general mental status, episodic memory, language, attention, executive function and visuospatial processing, and it showed significantly negative correlations with FC of multiple areas in the Default Mode Network (DMN) and Left Frontal-parietal Network (LFP) which are related to complex cognition. +3 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2019 year only

    Default Mode Network Connectivity in Alzheimers Disease

    ✓ Peer-reviewed Brain scans and imaging Turk psikiyatri dergisi = Turkish journal of psychiatry

    Key finding: Studies generally indicate a progressive impairment in DMN connectivity during the course of AD. +4 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2019 year only

    Use of amyloid PET/CT with 18F-Florbetaben in the management of patients with Alzheimer's disease

    ✓ Peer-reviewed Brain scans and imaging Hellenic journal of nuclear medicine

    Key finding: Twenty-five/38 (65.8%) amyloid PET/CT scans resulted positive for amyloid deposition. +4 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2019 year only

    Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction

    ✓ Peer-reviewed Brain scans and imaging Current Alzheimer research

    Key finding: These findings suggested that occipitoparietal cortex, posterior cingulate cortex and precuneus, which were particularly affected by increased tau accumulation in VS-AD patients, may associate with visuospatial dysfunction of AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  10. 2019 year only

    The Triggering Receptor Expressed on Myeloid Cells-2 (TREM-2) as Expression of the Relationship between Microglia and Alzheimer's Disease: A Novel Marker for a Promising Pathway to Explore

    ✓ Peer-reviewed TREM2 and immune genetics The Journal of frailty & aging

    Key finding: Alzheimer's disease (AD) is a common neurodegenerative disorder, strongly related with age. +2 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2019 year only

    Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms

    ✓ Peer-reviewed Genetics Advances in experimental medicine and biology

    Key finding: Interestingly, TREM2 and many genes associated with disease risk are predominantly expressed in microglia, suggesting that these risk factors are involved in pathogenicity through common mechanisms involving microglia. +1 more finding

    Full summary, score breakdown and related studies → Original source

  12. 2019 year only

    Leukocyte Telomere Length Shortening and Alzheimer's Disease Etiology

    ✓ Peer-reviewed Genetics Journal of Alzheimer's disease : JAD

    Key finding: The genetic risk score for TL was associated with higher risk of AD [log-odds ratio (OR) = 0.003 for per TL-decreasing allele; 95% confidence interval (CI): 0.001, 0.005, p = 0.005]. +2 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2019 year only

    Polygenic Risk Score Analysis of Alzheimer's Disease in Cases without APOE4 or APOE2 Alleles

    ✓ Peer-reviewed Genetics The journal of prevention of Alzheimer's disease

    Key finding: The We and others have previously shown that polygenic risk score analysis (PRS) has considerable predictive utility for identifying those at high risk of developing Alzheimer's disease (AD) with an area under the curve (AUC) of >0.8. +2 more findings

    Full summary, score breakdown and related studies → Original source

  14. 2019 year only

    Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study

    ✓ Peer-reviewed Tau biomarkers Journal of Alzheimer's disease : JAD

    Key finding: Patients with iNPH showed significantly lower levels of Aβ42, Aβ40, t-tau, and p-tau compared to controls. +2 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2019 year only

    Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases

    ✓ Peer-reviewed Tau biomarkers Journal of Alzheimer's disease : JAD

    Key finding: Significantly decreased Aβ42 levels and an increased Aβ40/42 ratio in CSF in ADD/MCI suggested that these relationships were specifically altered in AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  16. 2019 year only

    Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy

    ✓ Peer-reviewed Tau biomarkers Advances in experimental medicine and biology

    Key finding: After discovery of presence and increased levels tau in CSF from AD patients using specific ELISA, numerous reports revealed that CSF levels of tau are increased in AD and brain injury, phosphorylated tau are specifically increased in AD.

    Full summary, score breakdown and related studies → Original source

  17. 2019 year only

    The Panama Aging Research Initiative Longitudinal Study

    ✓ Peer-reviewed Biomarkers MEDICC review

    Key finding: Information was collected regarding limitations in activities of daily living, symptoms of depression and fall incidents. +4 more findings

    Full summary, score breakdown and related studies → Original source

  18. 2019 year only

    A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer's Disease

    ✓ Peer-reviewed Biomarkers Journal of Alzheimer's disease : JAD

    Key finding: Here we describe a novel extramembrane fragment from solute carrier family 38 member 10 (SLC38A10, S38AA) that we found to be decreased in pyramidal neurons in AD cases by proteomics and immunohistochemical analysis. +1 more finding

    Full summary, score breakdown and related studies → Original source

  19. 2019 year only

    Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease

    ✓ Peer-reviewed Biomarkers Dialogues in clinical neuroscience

    Key finding: To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. +4 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2019 year only

    Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study

    ✓ Peer-reviewed Biomarkers Journal of Alzheimer's disease : JAD

    Key finding: To investigate amyloid-β (Aβ) in frontotemporal dementia (FTD), cerebrospinal fluid (CSF) Aβ38, Aβ40, and Aβ42 in frontotemporal lobar degeneration (FTLD; N = 18 genetically and/or pathologically confirmed and N = 8 FTD with concomitant amyotrophic lateral sclerosis) were compared with Alzheimer's disease (AD; pathological or Pittsburgh-compound-B Positron-emission-tomography (PIB-PET) positive; N = 25) and controls (N = 24). +2 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2019 year only

    Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease

    ✓ Peer-reviewed Biomarkers Journal of Alzheimer's disease : JAD

    Key finding: Plasma Aβ42/Aβ40 ratio was associated with PiB-PET, the ROC curve analysis revealing an AUC of 0.77 (95% CI: 0.66-0.87), with a sensitivity of 82% and specificity of 64%. +2 more findings

    Full summary, score breakdown and related studies → Original source

  22. 2019 year only

    Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates

    ✓ Peer-reviewed Biomarkers Journal of Alzheimer's disease : JAD

    Key finding: NFL discriminated patients from controls with an area under the curve of 0.914 (95% CI, 0.843-0.984; p < 0.001) (cut-off: 76.46 pg/mL; 94% sensitivity, 76.9% specificity). +4 more findings

    Full summary, score breakdown and related studies → Original source

  23. 2019-01-01

    Evaluation of Medicare Claims Data as a Tool to Identify Dementia

    ✓ Peer-reviewed Digital health tools Journal of Alzheimer's disease : JAD

    Key finding: Database linkage to Medicare claims records is an efficient and reasonably accurate tool to identify dementia cases in a population-based cohort. +2 more findings

    Full summary, score breakdown and related studies → Original source

  24. 2019-01-01

    Vascular dysfunction-The disregarded partner of Alzheimer's disease

    ✓ Peer-reviewed Vascular contributions Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood-brain barrier integrity and cerebral blood flow. +1 more finding

    Full summary, score breakdown and related studies → Original source

  25. 2019-01-01

    Blood-Brain Barrier: From Physiology to Disease and Back

    ✓ Peer-reviewed Vascular contributions Physiological reviews

    Key finding: We conclude with lessons learned and future directions, with emphasis on technological advances to investigate the BBB functions in the living human brain, and at the molecular and cellular level, and address key unanswered questions.

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →